- Conditions
- Solid Tumor
- Interventions
- 177Lu-FAP-2286, 68Ga-FAP-2286
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 222 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Duarte, California • Irvine, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 505–528
of 1,660
matching trials from the local directory fallback.
- Conditions
- Advanced Solid Tumor, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, MSI-H Cancer, Metastatic Solid Tumor, dMMR Cancer
- Interventions
- Immunotherapy, Irinotecan, MOMA-341
- Drug
- Lead sponsor
- MOMA Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Diego, California • Tampa, Florida + 6 more
- Conditions
- Advanced Solid Tumors
- Interventions
- ASP1002, Bevacizumab, Carboplatin, Docetaxel, Fluorouracil, Irinotecan, Leucovorin, Oxaliplatin, Pembrolizumab, Pemetrexed, Ramucirumab, Trifluridine-Tipiracil
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 798 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 15
- States / cities
- New Haven, Connecticut • Plainville, Connecticut • Gainesville, Florida + 11 more
- Conditions
- Carcinoma, Non-Small-Cell Lung, Endometrial Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, Squamous Cell Carcinoma of the Head and Neck, Triple Negative Breast Neoplasms
- Interventions
- PF-08046054, pembrolizumab
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 714 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Irvine, California • Orange, California + 12 more
- Conditions
- Urothelial Carcinoma
- Interventions
- disitamab vedotin, pembrolizumab
- Drug
- Lead sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 158
- States / cities
- Gilbert, Arizona • Anaheim, California • Arcadia, California + 96 more
- Conditions
- Brain Tumor, Brain Tumor - Metastatic, Brain Tumor, Adult Meningioma, Brain Tumor, Adult: Glioblastoma, Brain Tumor, Primary, Brain Tumor, Recurrent
- Interventions
- GammaTile
- Device
- Lead sponsor
- GT Medical Technologies, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 53
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Castro Valley, California + 45 more
- Conditions
- Able Bodied, Sleep Disordered Breathing
- Interventions
- Acetazolamide + supplemental oxygen + PAP therapy, Buspirone + PAP therapy, Zolpidem + PAP therapy
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Adult Acute Myeloid Leukemia
- Interventions
- mocravimod
- Drug
- Lead sponsor
- Priothera SAS
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 366 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 18 more
- Conditions
- Cardiovascular Diseases, Hypertension, Vascular Diseases
- Interventions
- Ultrasound Renal Denervation (Paradise™ Ultrasound Renal Denervation (uRDN) System)
- Device
- Lead sponsor
- ReCor Medical, Inc.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 2
- States / cities
- Detroit, Michigan
- Conditions
- Opioid Induced Respiratory Depression, Postoperative Respiratory Complications, Respiratory Complications
- Interventions
- Respiratory volume monitoring
- Diagnostic Test
- Lead sponsor
- Wayne State University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Peripheral Arterial Disease
- Interventions
- Clopidogrel (Plavix) Pharmacogenetic Test Reagents
- Drug
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 2
- States / cities
- Detroit, Michigan • Grand Rapids, Michigan
- Conditions
- Cardiovascular Health, Health Promotion
- Interventions
- Health Impact 360, Usual care - Wait list control
- Behavioral · Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 328 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 7
- States / cities
- Detroit, Michigan • Flint, Michigan
- Conditions
- Generalised Lipodystrophy, Partial Lipodystrophy
- Interventions
- Metreleptin
- Drug
- Lead sponsor
- Chiesi Farmaceutici S.p.A.
- Industry
- Eligibility
- Not listed
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2031
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Duarte, California • Atlanta, Georgia + 11 more
- Conditions
- Cancer Weight Loss
- Interventions
- Placebo, TCMCB07
- Drug
- Lead sponsor
- Endevica Bio
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • Los Angeles, California • Santa Monica, California + 22 more
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor
- Interventions
- 5 Fluorouracil, CHS-114, Cisplatin, Toripalimab
- Drug
- Lead sponsor
- Coherus Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 154 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 20
- States / cities
- Tucson, Arizona • Duarte, California • Aurora, Colorado + 16 more
- Conditions
- Advanced Melanoma
- Interventions
- Nivolumab, Nivolumab + Relatlimab, Pembrolizumab, Single-agent chemotherapy, Vusolimogene Oderparepvec
- Biological · Drug
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 50
- States / cities
- Gilbert, Arizona • La Jolla, California • Los Angeles, California + 42 more
- Conditions
- Prostate Cancer (Adenocarcinoma)
- Interventions
- ADT, Abiraterone, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, Enzalutamide
- Drug
- Lead sponsor
- Canadian Cancer Trials Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 374
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more
- Conditions
- Rectal Cancer
- Interventions
- Capecitabine, Fluoruracil, Leucovorin, Oxaliplatin, Radiation
- Drug · Radiation
- Lead sponsor
- Canadian Cancer Trials Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 105
- States / cities
- Phoenix, Arizona • Irvine, California • Los Angeles, California + 86 more
- Conditions
- Advanced Solid Tumors
- Interventions
- Ipilimumab, Nivolumab, Pembrolizumab, mRNA-4359
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 16
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more
- Conditions
- Oropharyngeal Cancer
- Interventions
- Ipsilateral and Contralateral Neck, Lymphatic Mapping with SPECT-CT
- Radiation · Other
- Lead sponsor
- Canadian Cancer Trials Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 28
- States / cities
- Corona, California • Duarte, California • Irvine, California + 21 more
- Conditions
- Arrythmia, Cardiomyopathies
- Interventions
- Conventional Management, Intra-Op Prophylactic VT ablation
- Other · Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Breast Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal Cancer, HER-2 Protein Overexpression, Non-small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Salivary Gland Cancer, Urothelial Carcinoma
- Interventions
- Zanidatamab
- Drug
- Lead sponsor
- Jazz Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 17
- States / cities
- Prescott, Arizona • Littleton, Colorado • Fort Myers, Florida + 14 more
- Conditions
- Large Cell Lymphoma, Diffuse, Refractory Cancer, Relapsed Cancer
- Interventions
- AutoSCT OR CAR T-cell Therapy, Epcoritamab, GDP
- Procedure · Drug
- Lead sponsor
- Dipenkumar Modi
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Detroit, Michigan • Dallas, Texas + 1 more
- Conditions
- Solid Tumor
- Interventions
- BHV-1530, Cemiplimab
- Drug
- Lead sponsor
- Biohaven Therapeutics Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 17
- States / cities
- Newport Beach, California • Denver, Colorado • Lake Mary, Florida + 14 more